vs
百利高（PRGO）与Rithm Capital Corp.（RITM）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是Rithm Capital Corp.的1.3倍（$1.1B vs $828.2M），Rithm Capital Corp.净利率更高（13.2% vs -127.8%，领先141.0%），Rithm Capital Corp.同比增速更快（508.5% vs -2.5%），过去两年百利高的营收复合增速更高（1.3% vs -17.9%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
Rithm Capital Corp.是总部位于美国纽约的投资管理机构，核心业务聚焦房地产投资与另类资产投资，依托专业的投研团队和成熟的市场运营经验，为合作伙伴及投资者提供优质的资产配置解决方案与长期收益回报。
PRGO vs RITM — 直观对比
营收规模更大
PRGO
是对方的1.3倍
$828.2M
营收增速更快
RITM
高出511.0%
-2.5%
净利率更高
RITM
高出141.0%
-127.8%
两年增速更快
PRGO
近两年复合增速
-17.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $828.2M |
| 净利润 | $-1.4B | $109.5M |
| 毛利率 | 32.6% | — |
| 营业利润率 | -116.0% | 29.9% |
| 净利率 | -127.8% | 13.2% |
| 营收同比 | -2.5% | 508.5% |
| 净利润同比 | -3093.9% | 27.7% |
| 每股收益（稀释后） | $-10.23 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGORITM
| Q1 26 | — | $828.2M | ||
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.0B | $1.1B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.0B | $768.4M | ||
| Q4 24 | $1.1B | $2.1B | ||
| Q3 24 | $1.1B | $619.5M | ||
| Q2 24 | $1.1B | $1.2B |
净利润PRGORITM
| Q1 26 | — | $109.5M | ||
| Q4 25 | $-1.4B | $85.0M | ||
| Q3 25 | $7.5M | $221.5M | ||
| Q2 25 | $-8.4M | $311.7M | ||
| Q1 25 | $-6.4M | $78.8M | ||
| Q4 24 | $-44.4M | $290.2M | ||
| Q3 24 | $-21.0M | $121.7M | ||
| Q2 24 | $-108.4M | $235.6M |
毛利率PRGORITM
| Q1 26 | — | — | ||
| Q4 25 | 32.6% | — | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | 37.0% | — |
营业利润率PRGORITM
| Q1 26 | — | 29.9% | ||
| Q4 25 | -116.0% | 13.8% | ||
| Q3 25 | 7.0% | 21.4% | ||
| Q2 25 | 4.3% | 25.2% | ||
| Q1 25 | 4.5% | 7.4% | ||
| Q4 24 | 10.0% | 23.8% | ||
| Q3 24 | 7.4% | 7.3% | ||
| Q2 24 | -2.5% | 23.6% |
净利率PRGORITM
| Q1 26 | — | 13.2% | ||
| Q4 25 | -127.8% | 5.7% | ||
| Q3 25 | 0.7% | 20.0% | ||
| Q2 25 | -0.8% | 25.6% | ||
| Q1 25 | -0.6% | 10.3% | ||
| Q4 24 | -3.9% | 14.0% | ||
| Q3 24 | -1.9% | 19.7% | ||
| Q2 24 | -10.2% | 19.2% |
每股收益（稀释后）PRGORITM
| Q1 26 | — | $0.12 | ||
| Q4 25 | $-10.23 | $0.09 | ||
| Q3 25 | $0.05 | $0.35 | ||
| Q2 25 | $-0.06 | $0.53 | ||
| Q1 25 | $-0.05 | $0.07 | ||
| Q4 24 | $-0.32 | $0.50 | ||
| Q3 24 | $-0.15 | $0.20 | ||
| Q2 24 | $-0.79 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $9.1B |
| 总资产 | $8.5B | $53.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRGORITM
| Q1 26 | — | — | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | $432.1M | $1.6B | ||
| Q2 25 | $454.2M | $1.6B | ||
| Q1 25 | $409.9M | $1.5B | ||
| Q4 24 | $558.8M | $1.5B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $542.8M | $1.2B |
总债务PRGORITM
| Q1 26 | — | — | ||
| Q4 25 | — | $35.4B | ||
| Q3 25 | — | $32.2B | ||
| Q2 25 | — | $31.2B | ||
| Q1 25 | — | $32.2B | ||
| Q4 24 | — | $32.6B | ||
| Q3 24 | — | $29.6B | ||
| Q2 24 | — | $30.1B |
股东权益PRGORITM
| Q1 26 | — | $9.1B | ||
| Q4 25 | $2.9B | $8.4B | ||
| Q3 25 | $4.4B | $8.5B | ||
| Q2 25 | $4.5B | $7.9B | ||
| Q1 25 | $4.4B | $7.8B | ||
| Q4 24 | $4.3B | $7.8B | ||
| Q3 24 | $4.6B | $7.7B | ||
| Q2 24 | $4.5B | $7.3B |
总资产PRGORITM
| Q1 26 | — | $53.4B | ||
| Q4 25 | $8.5B | $53.1B | ||
| Q3 25 | $10.1B | $47.2B | ||
| Q2 25 | $10.1B | $44.3B | ||
| Q1 25 | $9.8B | $45.3B | ||
| Q4 24 | $9.6B | $46.0B | ||
| Q3 24 | $11.2B | $42.3B | ||
| Q2 24 | $10.4B | $42.0B |
负债/权益比PRGORITM
| Q1 26 | — | — | ||
| Q4 25 | — | 4.20× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 3.92× | ||
| Q1 25 | — | 4.14× | ||
| Q4 24 | — | 4.18× | ||
| Q3 24 | — | 3.87× | ||
| Q2 24 | — | 4.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | — |
| 自由现金流经营现金流 - 资本支出 | $148.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $145.1M | — |
8季度趋势，按日历期对齐
经营现金流PRGORITM
| Q1 26 | — | — | ||
| Q4 25 | $175.4M | $-114.6M | ||
| Q3 25 | $51.7M | $-2.0B | ||
| Q2 25 | $75.9M | $-557.1M | ||
| Q1 25 | $-64.5M | $1.4B | ||
| Q4 24 | $312.6M | $-1.8B | ||
| Q3 24 | $42.2M | $768.1M | ||
| Q2 24 | $9.5M | $-55.7M |
自由现金流PRGORITM
| Q1 26 | — | — | ||
| Q4 25 | $148.6M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $56.7M | — | ||
| Q1 25 | $-90.0M | — | ||
| Q4 24 | $274.9M | — | ||
| Q3 24 | $15.1M | — | ||
| Q2 24 | $-18.9M | — |
自由现金流率PRGORITM
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 5.4% | — | ||
| Q1 25 | -8.6% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | -1.8% | — |
资本支出强度PRGORITM
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 2.7% | — |
现金转化率PRGORITM
| Q1 26 | — | — | ||
| Q4 25 | — | -1.35× | ||
| Q3 25 | 6.89× | -9.22× | ||
| Q2 25 | — | -1.79× | ||
| Q1 25 | — | 18.03× | ||
| Q4 24 | — | -6.04× | ||
| Q3 24 | — | 6.31× | ||
| Q2 24 | — | -0.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |
